Interference of the expression of IL-17 at the posttranscriptional level could enhance the apoptosis of LC cell lines via activation of the FAS/FASL pathway, suggesting that IL-17 can be targeted for therapeutic intervention against LC. Here, IL17A is linked to laryngotracheoesophageal cleft.